Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenomics in acute myeloid leukemia.

Pharmacogenomics - 1 Nov 2009

Roumier Christophe, Cheok Meyling H

Abstract excerpt

Acute myeloid leukemia (AML) in adults is a heterogeneous malignant pathology with a globally unfavorable prognosis. The classification of AML allows identification of subgroups with favorable prognosis. However, besides these specific subgroups, most patients will have an intermediate or unfavorable prognosis often resulting in induction failure, probably due to drug resistance of the leukemic blasts, and more...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to ATP Binding Cassette Transporter, Subfamily B
Share to ATP Binding Cassette Transporter, Subfamily B, Member 1

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chromosome Aberrations

Share to Leukemia, Myeloid, Acute

Share to Mutation

Share to Pharmacogenetics

Source

Identifiers

PMID: 19891558
DOI: 10.2217/pgs.09.130

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenomics in acute myeloid leukemia.PMID 19891558Read ↗

Pharmacogenomics and the Treatment of Acute Myeloid LeukemiaSemantic proximity Read ↗

The Evolving AML Genomic Landscape: Therapeutic Implications.Semantic proximity Read ↗

Genomic landscape in acute myeloid leukemia and its implications in risk classification and targeted therapiesSemantic proximity Read ↗

Treatment of Acute Myeloid Leukemia in the Era of Genomics—Achievements and Persisting ChallengesSemantic proximity Read ↗

[Research update on pharmacogenomics in acute leukemia - review].Semantic proximity Read ↗

Genetic Abnormalities and Challenges in the Treatment of Acute Myeloid LeukemiaSemantic proximity Read ↗

Pharmacogenetics and the treatment of chronic myeloid leukemia: how relevant clinically? An update.Semantic proximity Read ↗

Update on drug transporter proteins in acute myeloid leukemia: Pathological implication and clinical settingSemantic proximity Read ↗

Pharmacogenomics.Semantic proximity Read ↗

Molecular genetic pathways as therapeutic targets in acute myeloid leukemia.Semantic proximity Read ↗

An overview of novel therapies in advanced clinical testing for acute myeloid leukemia.Semantic proximity Read ↗

Genetic biomarkers of drug resistance: A compass of prognosis and targeted therapy in acute myeloid leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.